Geovax Labs Inc

GOVX

Company Profile

  • Business description

    Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

  • Contact

    1955 Lake Park Drive
    Suite 300
    SmyrnaGA30080
    USA

    T: +1 678 384-7220

    E: [email protected]

    https://www.geovax.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    19

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,718.91628.64-1.20%
FTSE 10010,881.5521.01-0.19%
HKSE23,753.84116.240.49%
NASDAQ24,528.97607.30-2.42%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,303.77130.090.92%
S&P 5007,423.84137.83-1.82%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,602.5731.78-0.87%

Market Movers